JPMorgan Chase & Co. Boosts Teladoc Health (NYSE:TDOC) Price Target to $266.00

Teladoc Health (NYSE:TDOC) had its price target lifted by JPMorgan Chase & Co. from $240.00 to $266.00 in a research report released on Thursday morning, The Fly reports. JPMorgan Chase & Co. currently has an overweight rating on the health services provider’s stock.

Other equities analysts also recently issued research reports about the company. SunTrust Banks raised their target price on Teladoc Health from $144.00 to $200.00 and gave the stock a hold rating in a research report on Wednesday, May 13th. They noted that the move was a valuation call. Wells Fargo & Co raised their target price on Teladoc Health from $105.00 to $135.00 and gave the stock an equal weight rating in a research report on Thursday, April 16th. Barclays raised their target price on Teladoc Health from $200.00 to $230.00 and gave the stock an equal weight rating in a research report on Thursday. CSFB raised their target price on Teladoc Health from $152.00 to $165.00 and gave the stock a neutral rating in a research report on Thursday, April 30th. Finally, Piper Sandler raised their target price on Teladoc Health from $220.00 to $232.00 and gave the stock an overweight rating in a research report on Thursday. Fifteen equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Teladoc Health currently has an average rating of Hold and a consensus target price of $195.04.

Shares of TDOC stock opened at $237.63 on Thursday. The stock has a 50 day moving average of $207.13 and a two-hundred day moving average of $158.76. The company has a current ratio of 6.14, a quick ratio of 6.14 and a debt-to-equity ratio of 0.45. Teladoc Health has a 12 month low of $54.58 and a 12 month high of $240.00.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, July 29th. The health services provider reported ($0.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.23) by ($0.11). Teladoc Health had a negative return on equity of 10.23% and a negative net margin of 13.22%. The firm had revenue of $241.03 million during the quarter, compared to the consensus estimate of $220.49 million. During the same quarter in the prior year, the business posted ($0.41) EPS. Teladoc Health’s revenue was up 85.0% compared to the same quarter last year. On average, equities analysts anticipate that Teladoc Health will post -1.41 earnings per share for the current fiscal year.

In related news, CEO Jason N. Gorevic sold 40,000 shares of Teladoc Health stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $170.26, for a total transaction of $6,810,400.00. Following the completion of the sale, the chief executive officer now directly owns 711,283 shares of the company’s stock, valued at $121,103,043.58. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO David William Sides sold 3,117 shares of Teladoc Health stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $216.67, for a total value of $675,360.39. Following the sale, the chief operating officer now directly owns 7,299 shares of the company’s stock, valued at $1,581,474.33. The disclosure for this sale can be found here. Insiders sold a total of 189,977 shares of company stock valued at $36,248,032 over the last three months. Insiders own 3.42% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Nuveen Asset Management LLC grew its stake in shares of Teladoc Health by 5.8% during the fourth quarter. Nuveen Asset Management LLC now owns 540,933 shares of the health services provider’s stock worth $45,287,000 after purchasing an additional 29,630 shares during the period. James Investment Research Inc. acquired a new stake in shares of Teladoc Health during the first quarter worth $71,000. Clear Street Markets LLC grew its stake in shares of Teladoc Health by 66.7% during the first quarter. Clear Street Markets LLC now owns 10,000 shares of the health services provider’s stock worth $1,550,000 after purchasing an additional 4,000 shares during the period. Janney Montgomery Scott LLC grew its stake in shares of Teladoc Health by 220.7% during the first quarter. Janney Montgomery Scott LLC now owns 16,437 shares of the health services provider’s stock worth $2,548,000 after purchasing an additional 11,312 shares during the period. Finally, AQR Capital Management LLC lifted its holdings in Teladoc Health by 828.4% during the first quarter. AQR Capital Management LLC now owns 76,640 shares of the health services provider’s stock worth $11,880,000 after acquiring an additional 68,385 shares in the last quarter. 97.14% of the stock is owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Recommended Story: How does a reverse stock split work?

The Fly

Analyst Recommendations for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.